News
MIRA
1.060
-1.85%
-0.020
Psychedelic: Optimi Health advances natural psilocybin extract
TipRanks · 2d ago
Mira Pharmaceuticals secures worldwide rights for Ketamir-2
TipRanks · 3d ago
MIRA Expands Global Ketamir-2 License for Clinical Development
TipRanks · 3d ago
MIRA PHARMACEUTICALS INC: ENTERED INTO AMENDMENT NO 1 TO EXCLUSIVE LICENSE AGREEMENT WITH MIRALOGX LLC - SEC FILING
Reuters · 3d ago
MIRA PHARMACEUTICALS INC - EXPANDS KETAMIR-2 PATENT PORTFOLIO TO 10 MAJOR MARKETS - SEC FILING
Reuters · 3d ago
MIRA Pharmaceuticals Executes Amendment To Its Exclusive Ketamir-2 License Agreement With MIRALOGX To Expand Licensed Territory
Benzinga · 3d ago
Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets
PUBT · 3d ago
Mira Pharmaceuticals management to meet with Maxim
TipRanks · 4d ago
Weekly Report: what happened at MIRA last week (0518-0522)?
Weekly Report · 6d ago
Weekly Report: what happened at MIRA last week (0511-0515)?
Weekly Report · 05/18 09:40
Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue
PUBT · 05/14 19:04
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
TipRanks · 05/14 18:50
Mira announces results from Phase 1 trial evaluating Ketamir-2
TipRanks · 05/14 16:26
MIRA Pharma Announces Unblinded Results From Completed Phase 1 Clinical Trial Evaluating Ketamir-2, Proprietary Selective Oral NMDA Receptor Modulator
Benzinga · 05/14 12:10
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results
TipRanks · 05/13 21:14
Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy
PUBT · 05/13 20:20
Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator
PUBT · 05/13 20:04
Mira announces acceptance of peer-reviewed SKNY-1 manuscript
TipRanks · 05/13 16:28
MIRA Pharmaceuticals Announces Acceptance And Publication Of A Peer-Reviewed Manuscript On SKNY-1 In The International Journal Of Molecular Sciences
Benzinga · 05/13 12:09
MIRA highlights SKNY-1 preclinical data in new publication
TipRanks · 05/13 12:00
More
Webull provides a variety of real-time MIRA stock news. You can receive the latest news about Mira Pharma through multiple platforms. This information may help you make smarter investment decisions.
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.